文献速递白血病

急性髓系白血病中的免疫检查点分子:管理双刃剑

Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword.
PubMed 文献 · Br J Haematol · 2018-01-09

本文综述共抑制信号通路在急性髓系白血病(AML)免疫逃逸中的作用,并讨论检查点阻断剂在AML治疗中的机会。文章指出,靶向CTLA-4和PD-1/PD-L1的检查点抑制剂已在癌症治疗中取得突破,但避免严重全身毒性仍是挑战。

要点

  • 共抑制信号通路在AML免疫逃逸中起关键作用。
  • 靶向CTLA-4和PD-1/PD-L1的检查点抑制剂在癌症治疗中取得突破。
  • 避免严重全身毒性仍是检查点阻断治疗的挑战。

核心结论

  • 本文综述共抑制信号在AML免疫逃逸中的参与,并讨论检查点阻断剂在AML治疗中的机会。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 通过上调抑制性检查点,肿瘤反应性T细胞和自然杀伤细胞反应可被强烈阻碍。
  • 靶向CTLA-4和PD-1/PD-L1的检查点抑制剂引入后在癌症治疗中取得突破,并带来令人印象深刻的临床反应。
  • 众多新的共抑制分子和新型联合疗法目前正在研究其增强抗肿瘤免疫和改善癌症患者生存的潜力。

关键数值与推荐

  • 原文未报告具体标准与数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出避免严重全身毒性仍是挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New immunotherapeutic interventions have revolutionized cancer treatment. The immune responsiveness of acute myeloid leukaemia (AML) was first demonstrated by allogeneic stem cell transplantation. In addition, milder immunotherapeutic approaches are exploited. However, the long-term efficacy of these therapies is hampered by various immune resistance and editing mechanisms. In this regard, co-inhibitory signalling pathways have been shown to play a crucial role. Via up-regulation of inhibitory checkpoints, tumour-reactive T cell and Natural Killer cell responses can be strongly impeded. Accordingly, the introduction of checkpoint inhibitors targeting CTLA-4 (CTLA4) and PD-1 (PDCD1, CD279)/PD-L1 (CD274, PDCD1LG1) accomplished a breakthrough in cancer treatment, with impressive clinical responses. Numerous new co-inhibitory players and novel combination therapies are currently investigated for their potential to boost anti-tumour immunity and improve survival of cancer patients. Although the challenge here remains to avoid severe systemic toxicity. This review addresses the involvement of co-inhibitory signalling in AML immune evasion and discusses the opportunities for checkpoint blockers in AML treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hobo W, Hutten TJA, Schaap NPM, et al. Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword. Br J Haematol. 2018. PMID: 29318591. doi:10.1111/bjh.15078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。